These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 27525386)
1. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386 [TBL] [Abstract][Full Text] [Related]
2. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Schlumberger M; Elisei R; Müller S; Schöffski P; Brose M; Shah M; Licitra L; Krajewska J; Kreissl MC; Niederle B; Cohen EEW; Wirth L; Ali H; Clary DO; Yaron Y; Mangeshkar M; Ball D; Nelkin B; Sherman S Ann Oncol; 2017 Nov; 28(11):2813-2819. PubMed ID: 29045520 [TBL] [Abstract][Full Text] [Related]
3. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Krajewska J; Olczyk T; Jarzab B Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165 [TBL] [Abstract][Full Text] [Related]
5. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231 [TBL] [Abstract][Full Text] [Related]
6. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200 [No Abstract] [Full Text] [Related]
7. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914 [No Abstract] [Full Text] [Related]
8. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946 [TBL] [Abstract][Full Text] [Related]
10. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277 [TBL] [Abstract][Full Text] [Related]
11. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Grüllich C Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794 [TBL] [Abstract][Full Text] [Related]
12. [Cabozantinib: Mechanism of action, efficacy and indications]. Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875 [TBL] [Abstract][Full Text] [Related]
13. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032 [TBL] [Abstract][Full Text] [Related]
14. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment. Dabelić N; Jukić T; Fröbe A Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884 [TBL] [Abstract][Full Text] [Related]
15. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198 [TBL] [Abstract][Full Text] [Related]
16. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Drilon A; Rekhtman N; Arcila M; Wang L; Ni A; Albano M; Van Voorthuysen M; Somwar R; Smith RS; Montecalvo J; Plodkowski A; Ginsberg MS; Riely GJ; Rudin CM; Ladanyi M; Kris MG Lancet Oncol; 2016 Dec; 17(12):1653-1660. PubMed ID: 27825636 [TBL] [Abstract][Full Text] [Related]
17. Cabozantinib in Thyroid Cancer. Fallahi P; Ferrari SM; Di Bari F; Materazzi G; Benvenga S; Miccoli P; Antonelli A Recent Pat Anticancer Drug Discov; 2015; 10(3):259-69. PubMed ID: 26152149 [TBL] [Abstract][Full Text] [Related]
18. Systemic treatment and management approaches for medullary thyroid cancer. Ernani V; Kumar M; Chen AY; Owonikoko TK Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392 [TBL] [Abstract][Full Text] [Related]
19. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. Capdevila J; Klochikhin A; Leboulleux S; Isaev P; Badiu C; Robinson B; Hughes BGM; Keam B; Parnis F; Elisei R; Gajate P; Gan HK; Kapiteijn E; Locati L; Mangeshkar M; Faoro L; Krajewska J; Jarzab B Thyroid; 2022 May; 32(5):515-524. PubMed ID: 35403447 [No Abstract] [Full Text] [Related]
20. Cabozantinib: a review of its use in patients with medullary thyroid cancer. Hoy SM Drugs; 2014 Aug; 74(12):1435-44. PubMed ID: 25056653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]